Portal de Periódicos da CAPES

Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development

2002; Elsevier BV; Volume: 12; Issue: 2 Linguagem: Inglês

10.1006/scbi.2001.0420

1096-3650

Israël Vlodavsky, Orit Goldshmidt, Eyal Zcharia, Ruth Atzmon, Zehava Rangini-Guatta, Michael Elkin, Tamar Peretz, Yael Friedmann,

Platelet Disorders and Treatments

Cleavage of heparan sulphate proteoglycans (HSPGs) affects the integrity and functional state of tissues and thereby fundamental normal and pathological phenomena involving cell migration and response to changes in the extracellular microenvironment. Heparanase, degrading heparan sulphate (HS) at specific intrachain sites, is synthesized as a latent ∼65 kDa protein that is processed at the N-terminus into a highly active ∼50 kDa form. The heparanase enzyme is preferentially expressed in human tumours and its overexpression in low-metastatic tumour cells confers a highly invasive phenotype in experimental animals. Heparanase also releases angiogenic factors and accessory fragments of HS from the tumour microenvironment and induces an angiogenic response in vivo. Heparanase may thus facilitate tumour cell invasion, vascularization and survival in a given microenvironment, all critical events in cancer progression. These observations, the anticancerous effect of heparanase-inhibiting molecules, and the unexpected identification of a single predominant functional heparanase suggest that the enzyme is a promising target for drug development.